

Effects of Oral Clonidine versus Pregabalin on Smooth Emergence from Sevoflurane in Adults undergoing Rhinoseptoplasty: A Randomised Controlled Trial

TABLES OF THE RESEARCH AFTER STATISTICIAN REVISION:

- Table 1: Demographic and operative data of the study groups.
- Table 2: Mean arterial pressure (MAP) changes among the studied groups.
- Table 3: Heart rate (HR) changes among the studied groups.
- Table 4: End-tidal sevoflurane concentration (ETsevo) among the study groups.
- Table 5: Recovery characteristics of the study groups
- Table 6: Mean Riker sedation-agitation scale (RSAS) among the studied groups
- Table 7: Operative and analgesia characteristics of the study groups.
- Table 8: Visual analogue score (VAS) of the postoperative pain among the study groups.
- Table 9: A comparison between studied groups as regards incidence of postoperative complications.

Table 1: Demographic and operative data (mean \pm SD):

Demographic data	Group P (N=50)	Group C (N=50)	Group O (N=50)	F test	<i>p</i> value
Age (y)	27.2 \pm 6.5	29.2 \pm 7.6	30.3 \pm 7.4	2.517	0.084
Sex (N) M/F	28/22	27/23	25/25	χ^2 1.0	0.6
BMI (kg/m ²)	24.8 \pm 3.7	25.1 \pm 3.8	25.5 \pm 3.6	0.5	0.9
Duration of operation (min)	67.9 \pm 15.2	62.5 \pm 15.6	68.1 \pm 15.8	2.1	0.1
Duration of anaesthesia (min)	76.5 \pm 15.3	70.6 \pm 15.3	77.3 \pm 17.0	2.673	0.07

Table (2): Mean arterial pressure (MAP) changes among the studied groups.

	Group P (No.=50)	Group C (No.=50)	Group O (No.=50)	One-way ANOVA	
	Mean±SD Median	Mean±SD Median	Mean±SD Median	F	P value
MAP base line	89.9±10.6 96	92.6±11.4 95	94.8±10.5 99	2.502	.085
MAP after medication	66.5±6.5 67	63.8±5.3 63	94.5±10.5 ● 99	253.300	<0.001*
MAP after induction	64.8±5.5 64	63.4±5.1 64	81.4±10.2 ● 80	93.510	<0.001*
MAP after intubation	66.5±6.5 67	63.8±5.3 63	101.4±13.7 ● 103.5	257.237	<0.001*
MAP 5-15 min	61.6±3.5 61	63.3±3.9 64	85.7±12.8 ● 88	142.540	<0.001*
MAP 20-30 min	65.9±3.9 65.3	66.1±4.7 65.2	90.7±8.5 ● 92.7	277.992	<0.001*
MAP 35-45 min	67.1±10.2 63	62.8±4.9 62.8	90.4±13.4 ● 95	107.854	<0.001*
MAP 50-60 min	64.2±3.5 63.3	62.9±4.6 63	90.6±9.5 ● 92.3	297.639	<0.001*
MAP 65-75 min	62.7±3.1 62.5	62.6±4.8 ◇ 63.3	86.4±9.8 ● 86.7	218.350	<0.001*
MAP 80-90 min	70.1±7.1 70	65.9±7.3 64.3	93.1±7.8 90.5	195.766	<0.001*

◇: Significance between Group C and Group P.

● Significant between the group and both other groups.

Table (3): Heart rate (HR) changes among the studied groups.

	Group P (No.=50)	Group C (No.=50)	Group O (No.=50)	One-way ANOVA	
	Mean±SD Median	Mean±SD Median	Mean±SD Median	F	P value
HR base line	95.7±8.8 93	95.4±8.8 95	95.6± 8.6 93	.008	.992
HR after medication	65.9±7.2 64	62.1±5.3 ◇ 61	95.3±9.4● 92	292.669	<0.001*
HR after induction	61.7±4.1 61	59.8±6.1 60.5	77.6±13● 79	65.089	<0.001*
HR after intubation	64.0±5.7 63	64.9±9.4 64	102.0±9.1● 100	344.593	<0.001*
HR 5-15 min	62.2±2 62.2	61.7±3.4 61.5	76.7±13.4● 74	55.360	<0.001*
HR 20-30 min	63.0±3.6 61.7	63.7±4.6 63	88.6±11.2● 92.3	199.499	<0.001*
HR 35-45 min	63.9±4.9 61.8	63.2±7.7 61	98.6±10.3● 99.3	323.606	<0.001*
HR 50-60 min	62.3±3 62.3	61.0±4.5 60	87.4±9.9● 89.3	261.457	<0.001*
HR 65-75 min	62.7±2.9 62.7	60.6±5 59	80.1±12.4● 82.5	92.163	<0.001*
HR 80-90 min	62.5±2.9 62.7	60.6±4.9 59.5	80.5±11.1● 83.5	116.494	<0.001*

◇: Significance between Group C and Group P.

● Significant between the group and both other groups.

Table (4): End-tidal sevoflurane concentration (ETsevo) among the study groups.

	Group P (No.=50)	Group C (No.=50)	Group O (No.=50)	One-way ANOVA	
	Mean±SD Median	Mean±SD Median	Mean±SD Median	F	P value
ETsevo After intubation	1.9±0.3 2	1.9±0.3 2	1.9±0.2 2	.351	.704
ETsevo 5-15 min	1.2±0.4 1.2	1.0±0.4◇ 1	1.8±0.2● 1.9	53.026	<0.001*
ETsevo 20-30 min	1.2±0.4 1.2	1.1±0.4 1.1	1.8±0.2● 1.9	51.467	<0.001*
ETsevo 35-45 min	1.2±0.4 1.1	1.2±0.5 1	1.8±0.3● 2	43.140	<0.001*
ETsevo 50-60 min	1.2±0.3 1.1	1.2±0.5 1	1.8±0.3● 2	39.743	<0.001*
ETsevo 65-75 min	1.3±0.4 1.4	1.3±0.5 1.5	1.8±0.3● 1.9	14.851	<0.001*
ETsevo 80-90 min	1.5±0.3 1.5	1.1±0.5 1	1.6±0.4● 1.9	4.567	<0.019*

◇: Significance between Group C and Group P.

● Significant between the group and both other groups.

Table 5: Recovery characteristics of the study groups.

	Group P (N=50)		Group C (N=50)		Group O (N=50)		χ^2	p-value
	no	%	no	%	no	%		
RSAS of emergence state					■			
1	0	0.0	0	0.0	0	0.0		
2	7	14.0	3	6.0	0	0.0		
3	26	52.0	22	44.0	0	0.0		
4	17	34.0	25	50.0	36	72.0	66.90	<0.001*
5	0	0.0	0	0.0	7	14.0		
6	0	0.0	0	0.0	4	8.0		
7	0	0.0	0	0.0	3	6.0		
Incidence of EA	0	0.0	0	0.0	■ 14	28.0	30.88	<0.001*
Incidence of emergence sedation	33	66.0	25	50.0	■ 0	0.0	49.98	<0.001*

The data are expressed as mean \pm SD, RSAS = Riker sedation agitation score.

RSAS is a score of 7 grades (1 to 7) represented as the number and percentage of patients who scored each grade. See appendix 1.

EA: RSAS \geq 5.

Emergence sedation: RSAS <4.

Table 6: Mean Riker sedation-agitation scale (RSAS) among the studied groups

	Group P (No.=50)	Group C (No.=50)	Group O (No.=50)	One-way ANOVA	
	Mean±SD Median	Mean±SD Median	Mean±SD Median	F	P value
Baseline (before premedication)	4.6± 0.5 5	4.6±0.5 5	4.4±0.5 4	0.9	0.387
Before induction	3.8±0.4 4	3.7±0.5 4	4.3±0.5 ● 4	26.2	0.001*
Before extubation	3.2±0.7 3	3.4± 0.6 3.5	4.5± 0.9● 4	43.2	0.001*
Immediately after extubation	3.6±0.6 ■ 4	3.2± 0.7 3	4.3± 0.7● 4	38.7	0.001*
5 minutes after extubation	3.6± 0.5■ 4	3.2±0.6 3	4.3± 0.6● 4	40.8	0.001*
At PACU admission	3.8±0.4 4	3.6±0.5 4	4.2± 0.5● 4	20.2	0.001*
After 5 minutes in PACU	3.9±0.4 4	4±0.2 4	4.1±0.5 ● 4	8.2	0.001*
After 15 minutes in PACU	3.9±0.3 4	3.8±0.4 4	4.1±0.4● 4	8.4	0.001*
After 30 minutes in PACU	4±0 4	4±0 4	4±0.1 4	1.0	.370

■ Significant between group P and C

● Significant between the group and both other groups

Table 7: Operative and analgesia characteristics of the study groups.

	Group P (N=50)		Group C (N=50)		Group O (N=50)		χ^2	p-value
	no	%	No	%	no	%		
Operative field visibility score			■					
0	1	2.0	7	14.0	1	2.0		
1	14	28.0	20	40.0	13	26.0		
2	13	26.0	18	36.0	15	30.0	33.1	<0.001*
3	22	44.0	5	10.0	15	30.0		
4	0	0	0	0	6	12.0		
	Mean \pm SD		Mean \pm SD		Mean \pm SD		F test	
Recovery time (min)	8.7 \pm 4.5		8.1 \pm 4.1		9.2 \pm 4.0		0.9	0.418
PACU stay time (min)	39.9 \pm 1.2 ●		40.0 \pm 1.2 ◇		54.0 \pm 8.1		146.1	<0.001*
Time for first postoperative analgesic requirement (min)	148.8 \pm 46.5 ●		131.9 \pm 34◇		81.2 \pm 36.0		40.2	<0.001*
Induction dose of propofol (mg)	111.2 \pm 13.4 ●		113.0 \pm 15.3 ◇		196.8 \pm 6.5		789.7	<0.001*
Intraoperative Fentanyl consumption (μg)	2.6 \pm 9.0 ●		2.7 \pm 9.3 ◇		53.5 \pm 21.7		202.9	<0.001*
Postoperative meperidine consumption (mg)	9.9 \pm 3.7 ●		11.0 \pm 5.2◇		30.3 \pm 5		282	<0.001*

● significance between Group P and Group O, ◇: Significance between Group C and Group O

■ Significant between the group and both other groups

Table (8): Visual analogue score (VAS) of the postoperative pain among the study groups.

	Group P (No.=50)	Group C (No.=50)	Group O (No.=50)	One-way ANOVA	
	Mean±SD Median	Mean±SD Median	Mean±SD Median	F	P value
VAS 0	1.6±0.6 2	2.1±0.5 2	3.4±2.2 ● 2	23.148	<0.001*
VAS 30 min	1.8±0.6 2	2.5±0.9 2	4.0±2.3 ● 3	27.405	<0.001*
VAS 1 h	1.6±0.5 2	2.1±0.7 2	4.0±2.5 ● 3	33.190	<0.001*
VAS 1.5 h	1.7±0.5 2	2.3±1.2 2	5.6±2.2 ● 6	100.416	<0.001*
VAS 2 h	1.9±0.6 2	2.5±0.8 2	4.0±2.1 ● 4	32.205	<0.001*
VAS 2.5 h	3.7±0.6 4	4.1±0.9 4	4.7±1.2 ● 4	15.605	<0.001*
VAS 3 h	2.3±1.1 ◇ 2	3.2±1.2 3	4.1±2.2 ● 4	17.592	<0.001*
VAS 3.5 h	2.2±0.9 ● 2	3.1±0.9 3	3.3±1.6 3	13.961	<0.001*
VAS 4 h	2±0.6 ◇ 2	2.6±1.1 2	3.4±1.6 ● 3	18.304	<0.001*
VAS 8 h	2.2±0.8 2	2.4±0.6 2	3.0±1.6 ● 2.5	7.207	<0.001*
VAS 12 h	2±0.5 2	2.3±0.7 2	2.3±1.1 2	2.008	.138
VAS 16 h	1.9±0.5 2	2.1±0.6 2	2.1±0.7 2	.964	.384
VAS 20 h	2±0.5 2	2.3±0.7 2	2.1±0.8 2	2.738	.068
VAS 24 h	2±0.5 2	2.3±0.8 2	2.3±1.3 2	1.822	.165

◇: Significance between Group P and Group C

● Significant between the group and both other groups

Table 9: A comparison between studied groups as regards incidence of postoperative complications.

	Group P (N=50)		Group C (N=50)		Group O (N=50)		χ^2	P-value
	no	%	No	%	no	%		
Hypertension	0	0.0	0	0.0	21 [•]	42.0	48.8	<0.001*
Hypotension	4	8.0	10 [▪]	20.0	0	0.0	12	0.003*
Tachycardia	0	0.0	0	0.0	24 [•]	48.0	57.1	<0.001*
Bradycardia	0	0.0	6 [•]	12.0	0	0.0	12.5	0.002*
Shivering	0	0.0	0	0.0	7 [•]	14.0	14.7	0.001*
Headache	3	6.0	2	4.0	13 [•]	26.0	14.0	0.001*
Nausea	0	0.0	4	8.0	6	12.0	6.0	0.060
Vomiting	0	0.0	2	4.0	6	12.0	7.4	0.050
Dizziness	3	6.0	1	2.0	0	0.0	3.6	0.166
Visual disturbance	2	4.0	1	2.0	0	0.0	2.0	0.360

▪ Significant between group C and O

• Significant between the group and both other groups